Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku
Seeking Alpha News (Mon, 13-Jul 7:10 AM ET)
Cathie Wood Buys More SpaceX, Sells AMD, BioNTech, and Other Growth Stocks, 7/9/26
TipRanks (Thu, 9-Jul 12:05 AM ET)
Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
Business Wire (Wed, 27-May 8:00 AM ET)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Tue, 5-May 8:00 AM ET)
Twist Bioscience Now Accepts 99.5% of Clonal Genes Orders—Complex Gene Synthesis Meets Market Demand
Market Chameleon (Mon, 4-May 3:52 AM ET)
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
Business Wire (Mon, 4-May 7:20 AM ET)
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
Business Wire (Mon, 4-May 7:15 AM ET)
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
Business Wire (Tue, 21-Apr 8:00 AM ET)
Twist Bioscience Delivers Fiscal Q1 2026 Results—Innovative Platform Drives Growth Focus
Market Chameleon (Mon, 2-Feb 2:52 AM ET)
Twist Bioscience Highlights Robust Growth and Innovation in Fiscal 2025 Results
Market Chameleon (Fri, 14-Nov 3:18 AM ET)
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Twist Bioscience trades on the NASDAQ stock market under the symbol TWST.
As of July 13, 2026, TWST stock price declined to $90.35 with 814,764 million shares trading.
TWST has a beta of 0.85, meaning it tends to be less sensitive to market movements. TWST has a correlation of 0.02 to the broad based SPY ETF.
TWST has a market cap of $5.52 billion. This is considered a Mid Cap stock.
Last quarter Twist Bioscience reported $111 million in Revenue and -$.59 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.06.
In the last 3 years, TWST traded as high as $105.47 and as low as $14.42.
The top ETF exchange traded funds that TWST belongs to (by Net Assets): ARKK, ARKE, IWM, XBI, VTI.
TWST has outperformed the market in the last year with a return of +134.9%, while the SPY ETF gained +20.9%. In the last 3 month period, TWST beat the market returning +88.6%, while SPY returned +10.5%. However, in the most recent 2 weeks TWST has underperformed the stock market by returning -9.5%, while SPY returned +2.8%.
TWST support price is $86.28 and resistance is $94.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TWST shares will trade within this expected range on the day.